The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Systemic Sclerosis Mortality Rate May Be Underestimated

Systemic Sclerosis Mortality Rate May Be Underestimated

November 6, 2017 • By Kurt Ullman

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Biophoto Associates / Science Source; GN ILLUSTRATOR / SHUTTERSTOCK.COM

Biophoto Associates / Science Source; GN ILLUSTRATOR / SHUTTERSTOCK.COM

Systemic sclerosis (SSc) is a disease characterized by immunologic abnormalities, microvascular involvement and tissue fibrosis. In previous studies, 10-year survival rates ranged from 50–84%. However, there are concerns that these studies, using prevalent cohorts, are underestimating mortality.

You Might Also Like
  • Low Blood Pressure Increases Risk of Death in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
  • ANCA-Associated Vasculitis in Systemic Sclerosis
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
Explore This Issue
November 2017
Also By This Author
  • In Combined Clinic, a Rheumatologist & Dermatologist See Patients Together

“While the prognosis of many rheumatic diseases has improved with the availability of more effective and targeted therapies, mortality in SSc remains unacceptably high,” says Mandana Nikpour, MD, PhD, from the Departments of Rheumatology and Medicine at St. Vincent’s Hospital and the University of Melbourne, Australia. “Our goal was to accurately quantify the huge burden of mortality in scleroderma, highlighting the urgent need for new, effective therapies.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

International, Multi-Center Study

The researchers studied nearly 4,400 subjects over a median follow-up of 3.0 years (interquartile range 1.0 to 5.1 years). Information was obtained from the Australian Scleroderma Cohort Study, the Canadian Scleroderma Research Group, and the Madrid University Hospital 12 de Octubre Scleroderma Cohort Study. The Madrid group is a single-center cohort and the others are multi-center.1

The inception group (1,070 subjects) was defined as a subset of people recruited within four years of onset of first symptoms. The prevalent group (3,218) included all registered subjects, regardless of duration at entry.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Nikpour notes that all of those enrolled in the inception cohort were also included in the prevalent one. Because of this, they undertook extra analyses to remove inception cohort members from the prevalent cohort. Those remaining in the prevalent cohort were referred to as the non-inception cohort.

Followed from Onset

“We hypothesized that a lot of deaths occur early in the course of scleroderma and that the true burden of mortality can be underestimated unless a large cohort of patients is followed from early in the disease course (i.e., close to disease onset),” says Dr. Nikpour. “[Because] scleroderma is a relatively uncommon disease, in order to have a large enough group of patients followed from disease onset (inception cohort) to enable meaningful analyses, we needed to combine data from cohorts around the world.”

Dr. Nikpour

Dr. Nikpour

To do this, Dr. Nikpour and Yanjie Hao, MD, collaborated with Murray Baron, MD, and Marie Hudson, MD, MPH, of Montreal and Patricia Carreirs, MD, of Madrid to create a pooled data set of 1,070 incident cases from Australia, Canada and Spain. They compared mortality and causes of death with a pooled, prevalent cohort of patients recruited at various disease stages, sourced from the same countries. This inception cohort was the largest reported to date.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: heart-lung, mortality, organ damage, patient care, rate, renal complication, Research, rheumatologist, rheumatology, risk, Scleroderma, study, survival, Systemic sclerosis, Treatment, underestimatedIssue: November 2017

You Might Also Like:
  • Low Blood Pressure Increases Risk of Death in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
  • ANCA-Associated Vasculitis in Systemic Sclerosis
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • Heated Gloves May Improve Hand Function in Diffuse Systemic Sclerosis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)